CREBBP and lymphoma: Mutations in CREBBP (20%) and EZH2 (13%) were common in all progression cases of GCB COO, and lymphomas harboring alterations in these epigenetic modifiers may respond to histone deacetylase inhibitors (16) and enhancer of EZH2 inhibitors (17), respectively.